

Translation

Notice: This document is an excerpt translation of the original Japanese document and is for reference purposes only. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.

Tokyo, February 22, 2021
Alfresa Holdings Corporation

Notice regarding Establishment of Council for Personalized Medicine Support Platform “NOVUMN”

A subsidiary Alfresa Corporation (head office: Chiyoda-ku, Tokyo; President: Yusuke Fukujin; hereafter “Alfresa”) will establish a council with pharmaceutical wholesalers that use the service of a personalized medicine support platform NOVUMN*¹ on March 1, 2021, as specified below.

1. Purpose of Establishing the Council

Alfresa, PHC Corporation (head office: Minato-ku, Tokyo; President: Kyoji Morimoto; hereafter “PHC”), and Fujitsu Japan Limited (head office: Minato-ku, Tokyo; President: Toshio Hirose; hereafter “Fujitsu Japan”) have jointly developed NOVUMN, a personalized medicine support platform that utilizes RFID*², cloud-based infrastructure, and IoT*³ technologies, and have begun providing commercial services to medical institutions.

For specialty drugs whose active ingredients can be altered by minute changes in temperature, NOVUMN achieves strict temperature control throughout all stages of product distribution, traceability of individual pharmaceutical products, and improved inventory management functions for specialty drugs at pharmaceutical wholesalers and medical institutions. Through these functions, Alfresa aims to optimize the entire supply chain for specialty drugs.

With the aim of realizing such goals through the spread of NOVUMN, Alfresa, together with twenty-two pharmaceutical wholesalers utilizing NOVUMN service, PHC, and Fujitsu Japan, decided to establish the Personalized Medicine Traceability Council (hereafter “the Council”) on March 1, 2021.

2. Future Initiatives Planned by the Council

Companies participating in the Council will promote the popularization of NOVUMN in order to optimize the supply chain of specialty drugs. The main future initiatives planned by the Council are as follows:

- Publicity and awareness-raising initiatives for NOVUMN
- Surveys and research in order to improve NOVUMN
- Operation and management of the Council

3. List of Participant Companies at time of Council's Establishment (only pharmaceutical wholesalers listed*⁴)

Twenty-two participant companies

< Alfresa Group Companies >

 Alfresa Corporation	 Shikoku Alfresa Corporation	 ティーエスアルフレッサ株式会社	
 Meisho Co., Ltd.	 RYUYAKU CO., LTD.	 Tohoku Alfresa Corporation	
 ASTEM, Inc	 ATOL CO., LTD.	 IWABUCHI PHARMACEUTICAL CO., LTD.	 EVERLTH Co., Ltd
 Okano Pharmaceutical Co., Ltd.	 KSK Co., Ltd.	 TOMITA PHARMACEUTICAL CO., LTD.	 NAKAKITA YAKUHIIN CO., LTD
 Nakazawa Ujike Yakugyo K.K.	 VITAL-NET, INC.	 Finese Co., Ltd.	 HOKUYAKU Inc.
 MIYAZAKI ONSENDO SHOTEN CO. Ltd	 MEDICEO CORPORATION	 MOROO Co., LTD	 YONYAKU CO., LTD

*1 NOVUMN: Alfresa is currently applying for trademark registration

*2 RFID: Information is exchanged using RF tags embedded with ID information via short distance wireless communication (several centimeters to several meters, depending on the frequency band) using media such as electromagnetic fields and radio waves.

*3 IoT (Internet of Things): Systems in which a range of physical items are connected via the internet

*4 PHC and Fujitsu Japan will assist the operation of the Council as supporting members.


[Reference]

1. Outline of Personalized Medicine Traceability Council

Name of organization	Personalized Medicine Traceability Council (Abbreviation: PMT Council)
Date of establishment	March 1, 2021
Representative company	Alfresa Corporation
Participating companies at time of establishment (head office location)	<p><Twenty-two companies participating in the council></p> <p>◆ Alfresa Corporation (Chiyoda-ku, Tokyo)</p> <p>ASTEM, Inc (Fukuoka, Fukuoka Prefecture)</p> <p>ATOL CO., LTD. (Fukuoka, Fukuoka Prefecture)</p> <p>IWABUCHI PHARMACEUTICAL CO., LTD. (Yotsukaido, Chiba Prefecture)</p> <p>EVERLTH Co., Ltd (Hiroshima, Hiroshima Prefecture)</p> <p>Okano Pharmaceutical Co., Ltd. (Matsumoto, Nagano Prefecture)</p> <p>KSK Co., Ltd. (Osaka, Osaka Prefecture)</p> <p>◆ Shikoku Alfresa Corporation (Takamatsu, Kagawa Prefecture)</p> <p>◆ TS Alfresa Corporation (Hiroshima, Hiroshima Prefecture)</p> <p>◆ Tohoku Alfresa Corporation (Koriyama, Fukushima Prefecture)</p> <p>TOMITA PHARMACEUTICAL CO., LTD. (Kumamoto, Kumamoto Prefecture)</p> <p>NAKAKITA YAKUHIN CO., LTD (Nagoya, Aichi Prefecture)</p> <p>Nakazawa Ujike Yakugyo K.K. (Nankoku, Kochi Prefecture)</p> <p>VITAL-NET, INC. (Sendai, Miyagi Prefecture)</p> <p>Finese Co., Ltd. (Kanazawa, Ishikawa Prefecture)</p> <p>HOKUYAKU Inc. (Sapporo, Hokkaido Prefecture)</p> <p>MIYAZAKI ONSENDO SHOTEN CO. Ltd (Isahaya, Nagasaki Prefecture)</p> <p>◆ Meisho Co., Ltd. (Kanazawa, Ishikawa Prefecture)</p> <p>MEDICEO CORPORATION (Chuo-ku, Tokyo)</p> <p>MOROO Co., LTD (Sapporo, Hokkaido Prefecture)</p> <p>YONYAKU CO., LTD (Matsuyama, Ehime Prefecture)</p> <p>◆ RYUYAKU CO., LTD. (Urasoe, Okinawa Prefecture)</p>

* ◆ indicates it is an Alfresa Group company.

2. Conceptual diagram of the service offered by the NOVUMN



About Alfresa Group

The Alfresa Group is a leader in Japanese healthcare industry which is dedicated to make its corporate philosophy “we create and deliver a fresh life for all” come true through a wide range of business lines including ethical pharmaceutical wholesaling, OTC pharmaceuticals wholesaling, pharmaceutical manufacturing, and operating dispensing pharmacies. Alfresa Holdings Corporation (TSE:2784) reported its consolidated revenue of ¥2.7 trillion (US\$25 billion) for the fiscal year ended March 31, 2020. For more information, please see: <https://www.alfresa.com/eng/index.html>